<DOC>
	<DOC>NCT02737072</DOC>
	<brief_summary>The main purpose of this study is to evaluate the safety and tolerability of chemokine (C-X-C Motif) receptor 4 (CXCR4) peptide antagonist LY2510924 and durvalumab for phase 1a and 1b in participants with advanced refractory solid tumors.</brief_summary>
	<brief_title>A Study of LY2510924 and Durvalumab in Participants With Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Phase 1a: Have histologic or cytologic confirmation of advanced solid tumor Have at least 1 measurable lesion assessable using standard techniques by Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 Have adequate organ function Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale Have provided tissue from a newly obtained core or excisional biopsy of a tumor lesion or a recent biopsy defined by ≤3 years since last documented progression of disease Have an estimated life expectancy of ≥12 weeks, in the judgment of the investigator Have a serious concomitant systemic disorder including human immunodeficiency virus (HIV), active hepatitis B virus (HBV), active HCV, active autoimmune disorder or disease requiring high dose of steroids Have a bowel obstruction, history or presence of inflammatory enteropathy or extensive intestinal resection or chronic diarrhea Have evidence of interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drugrelated pulmonary toxicity or active, noninfectious pneumonitis Have an active infection requiring systemic therapy Have had prior therapy with an antiprogrammed cell death 1 (PD1), antiPDL1, antiPDL2, or anticytotoxic T lymphocyteassociated antigen4 antibody Moderate or severe cardiovascular disease Have symptomatic or uncontrolled brain metastases, spinal cord compression, or leptomeningeal disease requiring concurrent treatment Have received a live vaccine within 30 days before the first dose of study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>immuno-oncology</keyword>
</DOC>